Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2019 ( 76 )

2018 ( 397 )

2017 ( 421 )

2016 ( 482 )

Custom range...

Search Results: 1 - 10 of 24657 matches for " chronic hepatitis B "
All listed articles are free for downloading (OA Articles)
Page 1 /24657
Display every page Item
Changes of IL-1, TNF-Alpha, IL-12 and IL-10 Levels with Chronic Liver Failure  [PDF]
Guowang Liu, Kecheng Tang, Qian Li, Guiyu Yuan, Wukui Cao, Wei Lu
Surgical Science (SS) , 2011, DOI: 10.4236/ss.2011.22015
Abstract: [Aim] To investigate the action of cytokines in patients with chronic liver failure and to explore the roles of cytokines in chronic liver failure. [Methods] Thirty-one patients with chronic liver failure admitted from May 2006 to November 2009 were included. Thirty cases with mild to moderate chronic type B hepatitis admitted concomitantly were regarded as control. IL-1, TNF-alpha, IL-12, IL-10 Levels in serum was the factors to determine at clinical diagnosis and 2-week treatment. We analyzed levels of cytokines action in 31 chronic liver failure patients both at clinical diagnosis and 2-week treatment in comparison with control group. [Results] We analyzed IL-1 level in death group at clinical diagnosis and 2-week treatment were sig- nificant higher than in survival and control groups, furthermore it was also higher in survival group than in control group. At clinical diagnosis, TNF-alpha level in death group was higher than that in control. How- ever, there was no obviously difference between the death group and the survival group in TNF-alpha level. With the progression of the disease, TNF-alpha level was remarkably risen in death group, but decreased in survival group. IL-10 level was dramatically increased in death group, but no changed in survival group. IL-12 level in death group was higher than in survival group, but lower than in control group. [Conclusions] The levels of TNF-alpha, IL-1, IL-10 and IL-12 in patients with chronic liver failure was increased and the increase of IL-10 is secondary to elevation of IL-12.
HLA-DRB, DQA and DQB allele frequencies in Iranian patients with chronic hepatitis B by PCR-SSP
Baniaghil S,Sarafnejad A,Amirzargar A,Khosravi F
Tehran University Medical Journal , 2007,
Abstract: Background: The outcome of acute hepatitis B infection may be influenced by host genetic factors like human leukocyte antigen (HLA). To investigate the association between the HLA-DRB, DQA1 and DQB1 alleles and chronic hepatitis B infection, 50 patients with chronic hepatitis B (based on 6 months positive of HBsAg and HBc antibody and HBeAg and antibody by serological test), were selected from Turkman population in north east of Iran .Allele frequency in patients were compared with a 65 aged and sex match control group from healthy blood donor of that ethnic population. Methods: HLA DRB, DQA1 and DQB1 alleles were determined using polymerase chain reaction based on sequence specific primer (PCR-SSP) method. Allele frequencies in patients and control subjects were compared by Epi-info statistical soft-wear. Results: There was a significant increase and positive association in HLA-DRB1*0301, DQA1*0501 and DQB1*0604 allele frequency in patients group while the frequency of HLA-DRB1*1301, 1501 and DQB1*0401 and DQA1*0401, 0102 were lower in patients than control group and shows negative association. Conclusion: In Iranian Torkman population, HLA DRB1*0301, DQA1*0501 and DQB1*0604 have an important role in susceptibility to chronic hepatitis B infection and HLA DRB1*1301, 1501, DQB1*0401 are associated with protection to chronic hepatitis B infection. Larger case control studies may be helpful to confirm our investigation.
Hepatitis B Surface Antigen Serum Level Is Correlated with Fibrosis Severity in Treatment-Na?ve, Chronic Hepatitis B Patients in C?te d’Ivoire (West Africa)?  [PDF]
Mamert Fulgence Yao Bathaix, Dramane Soro, Aboubacar Demba Bangoura, Adjéka Stanislas Doffou, Siaka Koné, Ya Henriette Kissy, Dimitri Hartrydt Kouamé, Aoudi Ousmane Dé, Mahassadi Kouamé Alassane, Attia Koffi Alain, Aya Thérèse N’dri Yoman
Open Journal of Gastroenterology (OJGas) , 2015, DOI: 10.4236/ojgas.2015.511026
Abstract: HBsAg serum level (quantification) may be useful for managing hepatitis B virus (HBV) infection patients. However few studies especially in Africa have evaluated the association between HBsAg serum level and liver fibrosis severity. The objective of this study was to estimate the correlation between HBsAg serum level and liver fibrosis severity with treatment naive chronic hepatitis B patients in Cote d’Ivoire. Methodology: It is a prospective study covering from February 1st, 2014 to April 30st, 2015 at Centre Hospitalier et Universitaire de Yopougon and a private medical office in Abidjan, Cote d’Ivoire. Inclusion criteria for patients were: HBsAg positive, known HBeAg status, serum HBsAg levels, serum HBV DNA levels, complex serum markers and absence of HCV, HDV, or HIV co-infection, drinking more than 30 g/day for men and 20 g/day in women over 10 years, metabolic disease and/or hepatic overload. Pearson’s Chi-square test (r2), Anova, Spearman, T-Student, Pearson’s (r) correlations and Mann Withney’s Test were carried out as appropriate. A p value < 0.05 was taken as significant. Results: We recruited, 105 patients (77 men) of whom the medium age was 39.01 ± 9.72 years. Predominant hepatitis B viral genotype was E (93%). Less than 10% patients had an inactive HBV in HBeAg-negative. Patients had an average high HBsAg serum level (mean 12111.2 ± 10617.4 IU/ml) as well as the one viral load (mean 4.4 e7 ± 7.5 e7). Serum ALAT levels averaged at the upper limit of normal value. The average liver fibrosis score was 0.34 ± 0.22 and the degree of viral activity was 0.19 ± 0.20. Half of our patients had no fibrosis (35.24%) or had mild fibrosis (20.95%). No significant association was observed between HBsAg serum level and patient age (p = 0.3994), genre (p = 0.8075) or serum ALT levels (p = 0, 0787). In multivariate analysis, there’s a significant correlation (r = 0.239, p = 0.014) between HBV DNA levels and HBsAg serum level. There’s a significant correlation (r = 0.923, p < 0.0001) between HBsAg serum level and the dosage of alpha-fetoprotein. HBsAg serum level was not associated with the fibrosis stage (p = 0.281). HBsAg levels average with patients without fibrosis or carry a slight fibrosis (F0, F1) was higher than patients with moderate to severe fibrosis (F2, F3, F4): 13679.2 UI/ml ± 1956.48 versus 10610.52 UI/ml ± 8998.99 (p = 0.29). There’s a negative correlation between HBsAg level and the liver fibrosis score was negative (r = -0.069, p = 0.48). No significant association between HBsAg level and the liver fibrosis patients that were normal
Impact of Lamivudine plus Adefovir therapy in chronic hepatitis B Iranian patients, resistant to Lamivudine treatment alone, on disease inhibition: A pilot study  [PDF]
Arezoo Estakhri, Ashraf Mohamadkhani, Hosein Poustchi, Ghodrat Montazeri
Open Journal of Gastroenterology (OJGas) , 2012, DOI: 10.4236/ojgas.2012.22015
Abstract: AIM: To evaluate the impact of combination therapy with Lamivudine and Adefovir for treatment of chronic hepatitis B in Lamivudine-resistant patients. METHODS: Among the 110 adult chronic hepatitis B Iranian patients whom were treated with Lamivudine, for 36 months, nineteen patients (17%) with no any biochemical and viral responses to Lamivudine alone, were selected and enrolled in the study. Due to resistancy, Adefovir was added to Lamivudine, and continued for 30 months. We measured HBV_DNA viral load and serum AST, ALT in 0, 12, 24, 30 and 0, 6, 12, 18, 24, 30 months, respectively. RESULTS: Between biochemical and viral characteristics, Repeated Measure analysis identified just biochemical markers— Aspartate Aminotransferase level (AST) (P = 0.002) and Alanine Aminotransferase level (ALT) (P = 0.007) —as predictors of response to treatment, while, viral marker—HBV DNA load—was not statistically significant (P = 0.128). CONCLUSIONS: Treatment for a long time, such as 21.5 ± 8.8 months, with Lami- vudine and Adefovir, can cause liver enzymes including AST and ALT, decreasing and being normal. But, this finding is not indicative, for HBV-DNA viral load.
Prevalence of the hepatitis B surface antigen in a population of workers in Cameroon  [PDF]
Firmin Ankouane Andoulo, Michèle Tagni-Sartre, Dominique Noah Noah, Roger Djapa, Elie Claude Ndjitoyap Ndam
Open Journal of Gastroenterology (OJGas) , 2013, DOI: 10.4236/ojgas.2013.38057

Hepatitis B surface antigen prevalence in populations of blood donors in Cameroon is estimated at 6%-16%. As such, the Objective of this study was to determine the prevalence of Hepatitis B surface antigen in a population of bank employees, who represent a sample closer to the general population. In tests carried out both Yaounde and Douala in December 2011, we detected the hepatitis B surface antigen among 267 workers, including 151 men and 116 women of a median age of 37 years. The Results obtained revealed that the overall prevalence stood at 7.1%, with a 9.9% prevalence ratio in men, three times higher than that in women (3.4%). Subjects aged 20-29 years and senior staffs were more affected (each of them recording 8.1%). Potential nosocomial risks were detected mostly at the level of dental care (52.8%). Among the other risks of exposure, scarification (53.6%) was more frequent. A univariate analysis revealed an insignificant relationship with tattoos (OR 2.6, 95% CI 0.5-10.8, p = 0.2). These results led to the Conclusion that Hepatitis B surface antigen carrier prevalence in a population of workers in Cameroon is not different from that of blood donors. It is mainly due to early vertical and horizontal contamination.

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Patients Treated for Hepatitis B in the National University Hospital of Cotonou  [PDF]
Jean Sehonou, Aboudou Ra?mi Kpossou, Samuel Guido, Comlan N’dehougbea Martin Sokpon, Koffi Rodolph Vignon, Jacques Vigan
Open Journal of Gastroenterology (OJGas) , 2018, DOI: 10.4236/ojgas.2018.86024
Abstract: Introduction: Viral hepatitis B (VHB) is a serious and global public health issue, particularly in sub-Saharan Africa where it is endemic. The objective of this work was to evaluate the effectiveness and safety of tenofovir disoproxil fumarate (TDF) in the treatment of chronic VHB in Cotonou. Methods: This was a descriptive cross-sectional study with a retrospective collection of data from January 1st, 2015 to December 31st, 2016 (24 months) and prospective from May to August 2017 (4 months). Chronic VHB patients treated with TDF for at least 6 months were included. The non-detectability of HBV DNA and the normalization of aminotransferases defined the virological and biochemical responses, respectively. The evaluation of the treatment response on liver fibrosis was done by using APRI score. Renal impairment was assessed by a reduction in glomerular filtration rate according to MDRD (Modifications of the Diet in Renal Disease) formula below 90 mL/min/1.73 m2. Results: In all, 42 patients treated with TDF were included. The average age was 46.7 ± 13.8 years. The study population was predominantly male with a sex ratio of 2.5. Among the 42 patients treated with TDF for an average of 60 weeks (24 to 96 weeks), 36 patients (85.7%) had a virological response; 21 patients (50%) had a biochemical response. Virologic response was 70% at week 24 (W24), 92.6% at W48, 87.5% at W72 and 100% at W96 without significant difference between W24 and W48; between W48 and W72 then between W72 and W96. There was a regression of fibrosis and cirrhosis but not significantly. Renal involvement occurred in 3 out of 19 cases (15.8%) including a case of chronic end stage renal failure and 2 cases of mild chronic renal failure. Conclusion: The treatment with TDF is effective and globally safe in our patients with chronic viral hepatitis B in Cotonou.
A review of the use of telbivudine in the treatment of chronic hepatitis B
Prista Charuworn,Emmet B. Keeffe
Clinical Medicine : Therapeutics , 2009,
Abstract: Chronic hepatitis B is a major global health problem. Fortunately there are currently a number of agents licensed in most countries to treat chronic hepatitis B, including the oral nucleos(t)ide agents lamivudine, adefovir, entecavir, telbivudine, and tenofovir, and the immune modulators interferon alfa-2b and peginterferon alfa-2a. Large clinical trials have shown potent suppression of viral replication with telbivudine and a good safety profile, and superiority of telbivudine over lamivudine and adefovir in head-to-head trials. The potential of resistance with use of telbivudine mandates careful monitoring and on-treatment strategies to avoid or reduce the development of resistance. This review article provides an overview of the pharmacokinetics, clinical efficacy, safety, and resistance profile of telbivudine.
Influência da infec??o pregressa pelo vírus da hepatite B na fibrose hepática em portadores de hepatite C cr?nica: avalia??o retrospectiva de uma série de casos
Lisboa Neto, Gaspar;Tengan, Fatima Mitiko;Cavalheiro, Norma de Paula;Barone, Antonio Alci;
Revista da Sociedade Brasileira de Medicina Tropical , 2010, DOI: 10.1590/S0037-86822010000400016
Abstract: introduction: hepatitis c is a major cause of liver disease worldwide. its evolutionary course is dynamics and may be influenced by several cofactors. among them, previous hepatitis b virus infection (anti-hbcag [+] and hbsag [-]) has been associated with worse histological and therapeutic prognosis. this study had the objective of independently assessing the relationship between previous hepatitis b infection and liver fibrosis in patients with chronic hepatitis c. methods: the medical records of patients chronically infected with the hepatitis c virus who had been seen consecutively during a one-year period at the infectious and parasitic diseases outpatient clinic of hc fmusp were retrospectively reviewed in relation to epidemiological, clinical and histological data. analysis on the independence of the previous hepatitis b infection was performed using the statistical model of multivariate logistic regression. detection of anti-hbcag was taken to be the independent variable. the outcome was taken to be grade 3 and 4 histopathological abnormality (septa with nodule formation and cirrhosis). results: 145 subjects were evaluated in this study. 47.2% of them were anti-hbcag (+). the main risk factor for infection was blood and blood derivative transfusion (35.9%). findings of anti-hbcag (+) were not related to advanced liver fibrosis, although piecemeal necrosis has been found frequently in patients with this serological marker. conclusions: previous hepatitis b infection does not seem to increase the structural liver damage triggered by chronic hepatitis c virus infection, after statistical control for other co-factors capable to impact the natural history of this infection.
Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B Patients in Brazil
Costa, Anna Maria N.;L.'Italien, Gilbert;Nita, Marcelo Eidi;Araujo, Evaldo Stanislau A.;
Brazilian Journal of Infectious Diseases , 2008, DOI: 10.1590/S1413-86702008000500005
Abstract: hepatitis b virus infection is an important public-health issue. chronic patients have a higher risk of death due to complications, which increases health-care expenses in. cost-effectiveness analysis of entecavir (etv) versus lamivudine (lvd) for treatment of chronic hepatitis b, in e antigen (aghbe)-positive and negative patients, based on two phase 3, controlled and randomized studies. a decision analysis model was developed, using the following endpoints: cost per patient with undetectable viral load and cost per quality life year (qaly) gained. risks for complications (compensated or decompensated cirrhosis and hepatocellular carcinoma) were based on the cohort study reveal, published in 2006. the reveal parameters were applied to the results of the viral load levels obtained from the clinical assay data. the complication costs were based on a study of the disease cost conducted in brazil, in 2005. the cost data were obtained predominantly from sistema único de saúde [sus - brazilian public health system] payment tables and drug price lists. the utility data were obtained from literature and life expectancy information was based on ibge data. the analysis perspective was that of sus. a discount rate of 3% per year was used. for the horizon of time of 10 years, the etv had an incremental cost of approximately two million brazilian reais (r$) compared to lvd. reducing the number of complications, etv treatment reduced costs by around 3 million, reducing final costs by 1 million, for aghbe-positive patients. etv also reduced the incremental cost per qaly gained. etv was found to be the most cost-effective alternative for aghbe-positive and negative patients.
A Practical Approach to Management of Chronic Hepatitis B
Hu Ke-Qin
International Journal of Medical Sciences , 2005,
Abstract: Chronic hepatitis B (CHB) is one of the important public health problems worldwide. Major advances have been made in the treatment of CHB during the past several years. This article systemically reviews advances in the application of HBV DNA quantitation and three approved drugs for HBV treatment, and presents an updated and practical clinical approach to managing CHB. Highly sensitive PCR-based quantitation of HBV DNA makes it possible to precisely determine pre-treatment HBV load and monitor HBV DNA response during treatment. HBV DNA level, HBeAg status, degree of hepatic histological activity and fibrosis, and serum transaminases are the most important parameters in determining indication, regimen, and duration of HBV treatment. Although interferon alfa-2b, lamivudine, and adefovir are all approved as initial HBV treatment, understanding the advantages and advantages of each agent is important in choosing the best treatment for each individual patient with CHB.
Page 1 /24657
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.